<DOC>
	<DOC>NCT01649375</DOC>
	<brief_summary>This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are tolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor</brief_summary>
	<brief_title>16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or nonpregnant, nonlactating female patients Diagnosis of moderate to severe AS with prior documented radiologic evidence (xray) fulfilling the Modified New York criteria for AS (1984) Patients should have been on NSAIDs with an inadequate response Patients who are regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose Patients who have been on an antiTNFα agent (not more than one) must have experienced an inadequate response Chest Xray (or MRI) with evidence of ongoing infectious or malignant process Patients with total ankylosis of the spine Patients previously treated with any biological immunomodulating agents except for those targeting TNFα Previous treatment with any celldepleting therapies Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ankylosing spondylitis</keyword>
	<keyword>AS</keyword>
	<keyword>Chronic inflammatory disease</keyword>
	<keyword>Inflammatory back pain</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>Prefilled syringe (PFS)</keyword>
	<keyword>Subcutaneous injection</keyword>
	<keyword>AIN457</keyword>
	<keyword>AIN457F</keyword>
	<keyword>AIN457F2310</keyword>
</DOC>